Abstract
Hidradenitis suppurativa is a chronic recurrent inflammatory skin disease with abscess formation and scarring predominantly in the inverse areas. The disease is often difficult to treat and patients experience a decreased quality of life (QoL) and related psychosocial morbidity. Current knowledge on improving QoL in patients with hidradenitis suppurativa is therefore reviewed. The literature is limited but indicates that there are two ways of improving patients’ QoL: therapy of the somatic disease or psychosocial interventions.
Financial & competing interests disclosure
DN Dufour has been an investigator for Abbott Laboratories and has received speakers honoraria from Galderma. S Esmann has received speakers honoraria from Leo Pharma. GBE Jemec has been an investigator for Abbott Laboratories, Astellas, Astion Pharma, Coloplast, Galderma, Janssen-Cilag, Leo Pharma, Michaelson Diagnostics, MSD and Pfizer. He has received speakers honoraria from Abbott Laboratories, Coloplast, Galderma, Janssen-Cilag, Leo Pharma, MSD and Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Notes
Data taken from Citation[18].